GlassScriptPhysician profile
Alex Racco
NPI 1497783054
$11,988.37
in general payments reported to CMS, 2019-2025
46 companies · $1,544 in 2025
The $1,544 reported for 2025 was more than what 79% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,572 · 2020: $1,102 · 2021: $1,399 · 2022: $1,658 · 2023: $1,907 · 2024: $1,806 · 2025: $1,544.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,174 · Education: $83.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,173.78 |
| Education | $83.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,866.50 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,386.39 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $1,226.89 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Novo Nordisk INC | $1,100.79 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $919.09 | 2019-2025 | Mounjaro, Trulicity, Jardiance |
| Amgen INC. | $862.40 | 2019-2025 | Evenity, Otezla, Repatha |
| Pfizer INC. | $564.73 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $464.70 | 2019-2025 | Verquvo, Dificid, Steglatro |
| Novartis Pharmaceuticals Corporation | $455.95 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $399.04 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $339.02 | 2019-2025 | Jardiance, Synjardy |
| Takeda Pharmaceuticals U.S.A., INC. | $289.64 | 2019-2023 | Trintellix |
| Astellas Pharma US INC | $263.53 | 2019-2025 | Veozah, Myrbetriq |
| Sanofi-Aventis U.S. LLC | $212.20 | 2019-2022 | |
| Allergan, INC. | $168.99 | 2019-2020 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alex Racco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.